PHP12: ACUTE CARE ELDERLY UNITS: THEIR PREVALENCE, CHARACTERISTICS AND DETERMINANTS  by Jayadevappa, R et al.
172 Abstracts
Whether to legalise direct-to-consumer advertising
(DTCA), the authorised advertising of prescription drugs
direct to the consumer, within the European Union (EU)
is often discussed. But how would allowing DTCA help
EU governments looking for solutions to rising costs, ris-
ing patient expectations, loss of public confidence and
ageing populations? This poster summarises the main ar-
guments for and against the EU legalising DTCA. OB-
JECTIVES: To explore the arguments for and against al-
lowing the use of DTCA in EU states; to determine the
validity of the propounded arguments, by evaluating ac-
tual data which highlights the effects of introducing
DTCA in the US and New Zealand. METHODS: Using
PubMed and a within-literature search, a literature re-
view of published information on the arguments for and
against DTCA, and DTCA’s associated costs was under-
taken. RESULTS: Advocates believe DTCA will enable
the pharmaceutical industry to significantly improve the
effectiveness of its marketing campaigns. DTCA’s oppo-
nents argue that health care providers’ ability to ration
health care based on clinical need will be destroyed. US
data indicates that DTCA rose 38.5% in 1999 to
$US1.8bn, whilst in New Zealand expenditure rose
47.1% in 2000 to $US21.5m. DTCA has caused US retail
spending on prescriptions to soar. Yet in New Zealand
DTCA is credited with improving awareness, choice and
treatment of previously neglected conditions. CONCLU-
SIONS: DTCA’s ability to allow the pharmaceutical in-
dustry to connect with its ultimate consumers (patients)
would lead to increased strains on European health sys-
tems. But, the increased awareness that DTCA will bring
to currently neglected conditions (such as osteoarthritis
in men) could lead to huge benefits to patients quality-of-
lives and help refocus changing health systems towards
patients needs. As such, DTCA could be part of the solu-
tion to Europe’s health care crisis, but its introduction
will bring to EU states as many headaches as it solves.
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OBJECTIVES: The purpose of this study was to deter-
mine the relationship between health insurance coverage
(Medicare, Medicaid, other public, employer-sponsored,
and other private) and health care services utilization
(i.e., physician visits, hospitalizations, and the ability to
get needed prescription medications) among the elderly.
METHODS: The 1996 National Health Interview Survey
and its supplements were utilized as the data sources.
Elderly persons (65 years) who had Medicare coverage
(N  27,727,536) were included in the study. The
Andersen Health Care Services Utilization Behavioral
Model provided the study framework and was used to
understand the effect of health insurance coverage on
health care services utilization while controlling for other
variables. The framework models the relationship be-
tween predisposing (age, gender, living status, race, and
education), enabling (income, health insurance coverage,
usual source of care, geographic location, and out-of-pocket
spending), and need for care (health status, activity limi-
tation, restricted bed days, and comorbidities) factors
and health care services utilization. RESULTS: Elderly
persons with additional public health insurance coverage
(Medicare plus Medicaid or Medicare plus other public
health insurance) had significantly more physician visits
than those with Medicare only (p  0.0159 and 0.0258,
respectively). Elderly persons who had Medicare plus
other public health insurance and Medicare plus other
private health insurance were significantly more likely to
be hospitalized than those who had Medicare only (p 
0.0341 and 0.0327, respectively). Elderly persons with
Medicare plus employer-sponsored insurance were more
likely to get needed prescription medication(s) (p 
0.0076) than those with Medicare only. CONCLU-
SIONS: Elderly persons who had additional health insur-
ance coverage (i.e., in addition to Medicare) were more
likely to have more physician visits, hospitalizations, and
they were more likely to obtain needed prescription med-
ications. Additional health insurance coverage may be
beneficial in increasing access to health care services
among the elderly.
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BACKGROUND: The acutely ill hospitalized elderly pa-
tients face the risk of functional decline and poor quality
care. To improve the outcomes of hospitalization, vari-
ous intervention models have been used. However, the
contributors to the functional loss and quality of care are
interrelated and warrant a multidimensional interven-
tion. The Acute Care for Elders (ACE) unit is a one such
promising model of care for elderly to minimize adverse
outcomes of hospitalization. OBJECTIVE: To analyze
the determinants, prevalence and characteristics of ACE
units. METHODS: We surveyed all established Geriatric
Medicine Divisions (n  100) across US to determine
presence of ACE unit. Data on demographics, resource,
structure, administration, and patient care was obtained
via a questionnaire. Hospital data regarding number of
beds, revenue, number of medicare inpatients, and aver-
age length of stay was obtained from Annual Survey data
of the American Hospital Association. Descriptive analy-
sis and step-wise logistic regression were used to analyze
the characteristics and determinants of ACE units. RE-
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SULTS: Of the 82 responding geriatric divisions, 15 had
an active ACE unit. Average daily census on ACE units
ranged from 5 to 25, average length of stay was 5.2 days
and the average nurse to patient ratio was 1:6. Commu-
nity dwelling was the most common pre-admission living
setting. Two most common admitting diagnoses were
congestive heart failure and pneumonia. T-test showed
significant difference (.05) between hospitals with ACE
unit and hospitals without, with respect to number of
beds and total revenue. The step-wise logistic regression
indicated that total hospital revenue was the only signifi-
cant factor in determining the presence of an ACE unit.
CONCLUSIONS: Thus, application of the ACE unit
model remains modest given the paucity of information
regarding its long and short-term benefits and cost-effec-
tiveness. Further research in this direction can facilitate
informed policy decisions.
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OBJECTIVE: Given the high cost of pharmaceuticals,
particularly “blockbuster” drugs such as the COX-II in-
hibitors, the issue of value-for-dollar is an increasingly
important one for managed care decision-makers. Due to
the complexity of conducting full economic evaluations,
it is often tempting to try to reduce such analyses to the
most simplistic methods possible—either by assuming
equal effectiveness of two drugs and performing a cost-
minimization analysis, or by using an index of drug cost/
utilization such as DDD (number of defined daily doses
of a drug used in a population), PMPM (per member per
month cost/utilization), PPPM (per patient per month
cost/utilization), ADC (average daily cost of drug ther-
apy), or DACON (daily average consumption of a drug
in a population). If a partial economic evaluation based
on drug cost/utilization is necessary or preferred, deci-
sion-makers should bear in mind the relative strengths
and limitations of these approaches prior to making
policy decisions. The objectives of this paper are: (1) to
describe several indices of drug cost/utilization, (2) to dis-
cuss their strengths and limitations, (3) to provide
illustrations of their use, and (4) to offer suggestions for
appropriate interpretation. METHODS: Using numerical
examples focusing on COX-II inhibitors, several indices
of drug cost/utilization are described and compared, in-
cluding DDD, PMPM, PPPM, ADC, and DACON. Gen-
eral limitations and assumptions of “partial” economic
evaluations based solely upon cost/utilization data are
discussed, including assumptions of equal effectiveness,
compliance, continuation and safety; as well as con-
founding by indication, severity of illness and time on
market. RESULTS: Depending upon the index used, re-
sults (data) on drug cost/utilization for COX-II inhibitors
vary. CONCLUSION: Numerous indices are used to de-
scribe and evaluate drug cost/utilization. Each has its
own strengths and limitations, and must be interpreted in
the appropriate context to best inform pharmaceutical
policy decision-making.
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OBJECTIVES: The study purpose was to describe and
quantify annual costs of pharmaceutical services per cate-
gory (5) and clienteles (5) in a 452 bed mother and child
teaching institution. METHODS: Based on a daily diary
completed by each pharmacist, we calculated costs of
pharmaceutical services in five categories in 1999–2000:
distribution, management, clinical, teaching and research.
Pharmacists were requested to provide a description of
their activities, including the number of new patients/fol-
low-up, verbal and written requests and number/type of
interventions. Costs ratios were calculated. RESULTS:
1999–2000 fiscal year showed 21,330 admissions, 115,961
patient-days and 275,000 outpatient visits. Pharmacists
represented 47% of total worked hours. Pharmacists’ to-
tal hours reported represented 89,6 % of accounting
data. Hours were dedicated to distribution (53%), clini-
cal (29%), management (12%), teaching (5%) and re-
search (1%) services. Pharmacists answered 26 491 ques-
tions while providing 26 065 interventions among 5
clienteles (intensive care, pediatrics, multi-specialties,
mother and child and haematology/oncology). We calcu-
lated a ratio of interventions/worked hours with an aver-
age of 0,61 (min 0,015–max 1,35). An analysis of these
differences will be provided. Pharmacists’ total annual
costs represented $1,453,000.00 CDN including social
benefits. Assuming our pharmacy model optimizes the
number of potential interventions in our setting and that
100 % of pharmacist’s paid time is required to material-
ize them, we calculated an average cost of $54.92 CDN/
intervention (min $24.80 CDN–max $2,233.00 CDN).
Differences were calculated between 1998–1999 and
1999–2000 showing an average of 104% difference (min
68%–max 197%). Differences can be explained by phar-
macist expertise evolution, management decisions and
changes in activity volumes. CONCLUSION: There are
little data available to allow benchmarking in the costs of
pharmaceutical services. Further studies are required to
identify the most useful ratios to monitor such costs as
well as relevant outcomes.
